Literature DB >> 17437305

Contrasting potential of nitric oxide and peroxynitrite to mediate oligodendrocyte injury in multiple sclerosis.

Carolyn Jack1, Jack Antel, Wolfgang Brück, Tanja Kuhlmann.   

Abstract

Nitric oxide (NO) and peroxynitrite (ONOO(-)) are potential mediators of the injury and cytotoxicity occurring over time to oligodendrocytes in multiple sclerosis (MS) lesions. Our in vitro results indicate that human adult CNS-derived oligodendrocytes are relatively resistant to NO-mediated damage. In contrast, human oligodendrocytes are highly susceptible to peroxynitrite-mediated injury. In situ, we found that inducible nitric oxide synthase (iNOS) was expressed in astrocytes and macrophages in all active demyelinating and remyelinating MS lesions examined, yet no correlation was found between numbers of glial cells expressing iNOS and the extent of oligodendrocyte cell death. Nitrotyrosine groups, indicative of the presence of peroxynitrite in vivo, could be detected on astrocytes, macrophages, and oligodendrocytes in MS lesions. High numbers of nitrotyrosine-positive oligodendrocytes were found in one MS case that featured extensive oligodendrocyte cell death. Our results indicate that NO alone is unlikely to induce oligodendrocyte injury, whereas its more potent byproduct peroxynitrite is a potential mediator of injury to oligodendrocytes in MS. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437305     DOI: 10.1002/glia.20514

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  26 in total

1.  In vitro and in vivo induction and activation of nNOS by LPS in oligodendrocytes.

Authors:  S Y Yao; A Ljunggren-Rose; N Chandramohan; W O Whetsell; S Sriram
Journal:  J Neuroimmunol       Date:  2010-08-19       Impact factor: 3.478

2.  Differential sensitivity of oligodendrocytes and motor neurons to reactive nitrogen species: implications for multiple sclerosis.

Authors:  Amy Bishop; Kimberly Green Hobbs; Asuka Eguchi; Stephanie Jeffrey; Lorraine Smallwood; Cedona Pennie; James Anderson; Alvaro G Estévez
Journal:  J Neurochem       Date:  2009-01-19       Impact factor: 5.372

3.  Missing in Action: Dysfunctional RNA Metabolism in Oligodendroglial Cells as a Contributor to Neurodegenerative Diseases?

Authors:  Peter Hoch-Kraft; Jacqueline Trotter; Constantin Gonsior
Journal:  Neurochem Res       Date:  2019-03-06       Impact factor: 3.996

4.  Effect of 1400W on blocking lipopolysaccharide-induced microglial toxicity to preoligodendrocytes.

Authors:  Ya-Fang He; Hui-Jin Chen; Long-Huan Qian; Guan-Yi Chen
Journal:  World J Pediatr       Date:  2010-06-12       Impact factor: 2.764

5.  In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.

Authors:  In-Young Choi; Phil Lee; Peter Adany; Abbey J Hughes; Scott Belliston; Douglas R Denney; Sharon G Lynch
Journal:  Mult Scler       Date:  2017-06-01       Impact factor: 6.312

Review 6.  Multiple sclerosis: molecular mechanisms and therapeutic opportunities.

Authors:  Djordje Miljković; Ivan Spasojević
Journal:  Antioxid Redox Signal       Date:  2013-04-22       Impact factor: 8.401

Review 7.  Lame ducks or fierce creatures? The role of oligodendrocytes in multiple sclerosis.

Authors:  T Zeis; N Schaeren-Wiemers
Journal:  J Mol Neurosci       Date:  2008-02-16       Impact factor: 3.444

Review 8.  Neuroprotective effects of the complement terminal pathway during demyelination: implications for oligodendrocyte survival.

Authors:  Cosmin A Tegla; Cornelia Cudrici; Violeta Rus; Takahiro Ito; Sonia Vlaicu; Anil Singh; Horea Rus
Journal:  J Neuroimmunol       Date:  2009-07-04       Impact factor: 3.478

9.  Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis.

Authors:  Fotini Pittas; Anne-Louise Ponsonby; Ingrid A F van der Mei; Bruce V Taylor; Leigh Blizzard; Patricia Groom; Obioha C Ukoumunne; Terry Dwyer
Journal:  J Neurol       Date:  2009-04-09       Impact factor: 4.849

10.  Inhibition of myeloperoxidase at the peak of experimental autoimmune encephalomyelitis restores blood-brain barrier integrity and ameliorates disease severity.

Authors:  Hao Zhang; Avijit Ray; Nichole M Miller; Danielle Hartwig; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  J Neurochem       Date:  2015-11-30       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.